CGM Continues to Evolve

CGMs(Continuous Glucose Monitors) today need to be replaced every 7,10, or 14 days and can be complex and burdensome for some patients.

Technologies currently available on the market have issues that may impact acceptance, including:

  • Short sensor life
  • Accuracy limitations
  • Issues with sensor self-insertion and removal
  • Issues with skin irritations caused by adhesives 

The Eversense® Difference

The Eversense® CGM system balances performance, safety and patient experience with a professionally implanted sensor that lasts up to 90 days.

It was designed for simplicity and continuous feedback, so it's a great fit for patients who are striving for better self-management and desire low complexity.

Imagine an Easier, More Reliable Way For Your Patients to Manage Diabetes With:

A professionally inserted sensor that fits comfortably under your patient's skin and lasts for up to 90 days

Removable and re-attachable transmitter provides flexibility without wasting a sensor

On-body vibrations that alert your patient when glucose levels are either too high or too low

An easy way for your patients to automatically share important data with you

Helps to Overcome Challenges that Patients May Experience Including:3

 
  • Dexterity
  • Complexity
  • Memory
  • Audio and visual challenges

Key Benefits of the Eversense® System, Include:

 
  • Adherence–improved with easy to remove and reapply transmitter
  • Exceptional accuracy with a MARD of 8.5%1
  • Clinically proven to help lower A1c2
  • On-body vibratory patient alerts1,3
  • Data can be shared with Health Care Provider, friends and family
  • Under-the-skin sensor helps patients reach unprecedented levels of wear time (90 days)2
  • Sensor is protected in a subcutaneous pocket eliminating accidental dislodging
  • Fewer insertions–4 versus up to 26-52 per year
 

4 Simple Questions to Determine Medicare Eligibility4

Therapeutic CGMs are considered reasonable and necessary by Medicare when all following coverage criteria are met:

  1. The beneficiary has diabetes mellitus; and,
  2. The beneficiary is insulin-treated with multiple (three or more) daily administrations of insulin or a Medicare-covered continuous subcutaneous insulin infusion (CSII) pump; and,
  3. The beneficiary's insulin treatment regimen requires frequent adjustment by the beneficiary on the basis of blood glucose monitor (BGM) or CGM testing results (note: some regional Medicare Administrative Contractors may require documentation of 4 or more fingerstick blood glucose checks daily); and,
  4. Within six (6) months prior to ordering the CGM, the treating practitioner has an in person visit with the beneficiary to evaluate their diabetes control and determined that criteria (1-3) above are met4 (note: some regional Medicare Administrative Contractors may require every 6-month visits); and, routine recommended follow-up care is expected.

Learn More about Ordering and Reimbursement

Contact Us

The Eversense CGM system can make a significant difference in your Medicare patients' lives. For more information on Medicare coverage for your patients, please contact your sales representative or click on this link. It will be our pleasure to answer any questions you may have about Eversense.

  1. Eversense CGM System Summary of Safety and Effectiveness Data (SSED) #P160048.
  2. Christiansen MP, Klaff LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206.
  3. Engler R, Routh TL, Lucisano JY. Adoption Barriers for Continuous Glucose Monitoring and Their Potential Reduction With a Fully Implanted System: Results From Patient Preference Surveys. Clinical Diabetes. 2018;36(1):50-58. doi:10.2337/cd17-0053.
  4. Centers for Medicare & Medicaid Services : Medicare Coverage Database(MCD) (2020 October 17) Retrieved March 24, 2021, From https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=38659